{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:16:40Z","timestamp":1794395800321,"version":"4.9.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12969-018-0296-z","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T13:08:01Z","timestamp":1544792881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review"],"prefix":"10.1186","volume":"16","author":[{"given":"Ju-Yang","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hee","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-3367","authenticated-orcid":false,"given":"Hyoun-Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"key":"296_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.it.2012.07.003","volume":"33","author":"M Rincon","year":"2012","unstructured":"Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 2012;33:571\u20137.","journal-title":"Trends Immunol"},{"key":"296_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7","volume":"43","author":"CM Weyand","year":"2000","unstructured":"Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43:1041\u20138.","journal-title":"Arthritis Rheum"},{"key":"296_CR3","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T. IL-6: regulator of Treg\/Th17 balance. Eur J Immunol. 2010;40:1830\u20135.","journal-title":"Eur J Immunol"},{"key":"296_CR4","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","volume":"10","author":"LH Calabrese","year":"2014","unstructured":"Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol. 2014;10:720\u20137.","journal-title":"Nat Rev Rheumatol"},{"key":"296_CR5","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.4049\/jimmunol.141.5.1543","volume":"141","author":"M Okada","year":"1988","unstructured":"Okada M, Kitahara M, Kishimoto S, et al. IL-6\/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988;141:1543\u20139.","journal-title":"J Immunol"},{"key":"296_CR6","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/0092-8674(90)90411-7","volume":"63","author":"M Hibi","year":"1990","unstructured":"Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990;63:1149\u201357.","journal-title":"Cell"},{"key":"296_CR7","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.V86.4.1243.bloodjournal8641243","volume":"86","author":"T Kishimoto","year":"1995","unstructured":"Kishimoto T, Akira S, Narazaki M, et al. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243\u201354.","journal-title":"Blood"},{"key":"296_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0092-8674(89)90438-8","volume":"58","author":"T Taga","year":"1989","unstructured":"Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989;58:573\u201381.","journal-title":"Cell"},{"key":"296_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1126\/science.1411569","volume":"258","author":"T Kishimoto","year":"1992","unstructured":"Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992;258:593\u20137.","journal-title":"Science"},{"key":"296_CR10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.V82.4.1120.1120","volume":"82","author":"M Narazaki","year":"1993","unstructured":"Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993;82:1120\u20136.","journal-title":"Blood"},{"key":"296_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2165\/00003495-200969050-00007","volume":"69","author":"V Oldfield","year":"2009","unstructured":"Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009;69:609\u201332.","journal-title":"Drugs"},{"key":"296_CR12","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1016\/j.febslet.2011.03.023","volume":"585","author":"T Tanaka","year":"2011","unstructured":"Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 2011;585:3699\u2013709.","journal-title":"FEBS Lett"},{"key":"296_CR13","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.39740","volume":"68","author":"L Lally","year":"2016","unstructured":"Lally L, Forbess L, Hatzis C, et al. Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia Rheumatica. Arthritis Rheumatol. 2016;68:2550\u20134.","journal-title":"Arthritis Rheumatol"},{"key":"296_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/acr.20319","volume":"63","author":"X Puechal","year":"2011","unstructured":"Puechal X, DeBandt M, Berthelot JM, et al. Tocilizumab in refractory adult Still's disease. Arthritis Care Res (Hoboken). 2011;63:155\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"296_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10067-012-2105-2","volume":"32","author":"H Boysson de","year":"2013","unstructured":"de Boysson H, Fevrier J, Nicolle A, et al. Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence. Clin Rheumatol. 2013;32:141\u20137.","journal-title":"Clin Rheumatol"},{"key":"296_CR16","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nrrheum.2010.121","volume":"6","author":"S Kamphuis","year":"2010","unstructured":"Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010;6:538\u201346.","journal-title":"Nat Rev Rheumatol"},{"key":"296_CR17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1681\/ASN.V76924","volume":"7","author":"N Baqi","year":"1996","unstructured":"Baqi N, Moazami S, Singh A, et al. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol. 1996;7:924\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"296_CR18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4049\/jimmunol.147.1.117","volume":"147","author":"M Linker-Israeli","year":"1991","unstructured":"Linker-Israeli M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol. 1991;147:117\u201323.","journal-title":"J Immunol"},{"key":"296_CR19","first-page":"16","volume":"40","author":"M Iwano","year":"1993","unstructured":"Iwano M, Dohi K, Hirata E, et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol. 1993;40:16\u201321.","journal-title":"Clin Nephrol"},{"key":"296_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.27221","volume":"62","author":"GG Illei","year":"2010","unstructured":"Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542\u201352.","journal-title":"Arthritis Rheum"},{"key":"296_CR21","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/0961203312441046","volume":"21","author":"K Maeshima","year":"2012","unstructured":"Maeshima K, Ishii K, Torigoe M, et al. Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus. Lupus. 2012;21:1003\u20136.","journal-title":"Lupus"},{"key":"296_CR22","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/rheumatology\/kes072","volume":"51","author":"FJ Garcia-Hernandez","year":"2012","unstructured":"Garcia-Hernandez FJ, Gonzalez-Leon R, Castillo-Palma MJ, et al. Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus. Rheumatology (Oxford). 2012;51:1918\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"296_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/RHU.0b013e31823ecd73","volume":"18","author":"A Makol","year":"2012","unstructured":"Makol A, Gibson LE, Michet CJ. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol. 2012;18:92\u20135.","journal-title":"J Clin Rheumatol"},{"key":"296_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3109\/14397595.2014.990409","volume":"27","author":"A Iwai","year":"2017","unstructured":"Iwai A, Naniwa T, Tamechika S, et al. Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvements including massive pericarditis and glomerulonephritis. Mod Rheumatol. 2017;27:529\u201332.","journal-title":"Mod Rheumatol"},{"key":"296_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4078\/jrd.2018.25.2.144","volume":"25","author":"MY Kim","year":"2018","unstructured":"Kim MY, Park S, Suh CH, et al. Patient with systemic lupus erythematosus combined with erosive arthritis was treated successfully with tocilizumab: a case report. J Rheum Dis. 2018;25:144\u20137.","journal-title":"J Rheum Dis"},{"key":"296_CR26","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","volume":"371","author":"BM Feldman","year":"2008","unstructured":"Feldman BM, Rider LG, Reed AM, et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371:2201\u201312.","journal-title":"Lancet"},{"key":"296_CR27","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/nrrheum.2011.139","volume":"7","author":"AB Robinson","year":"2011","unstructured":"Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol. 2011;7:664\u201375.","journal-title":"Nat Rev Rheumatol"},{"key":"296_CR28","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"53","author":"T Gono","year":"2014","unstructured":"Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford). 2014;53:2196\u2013203.","journal-title":"Rheumatology (Oxford)"},{"key":"296_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12969-015-0048-2","volume":"13","author":"H Wakiguchi","year":"2015","unstructured":"Wakiguchi H, Hasegawa S, Hirano R, et al. Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels. Pediatr Rheumatol Online J. 2015;13:49.","journal-title":"Pediatr Rheumatol Online J"},{"key":"296_CR30","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1002\/art.34659","volume":"64","author":"AM Reed","year":"2012","unstructured":"Reed AM, Peterson E, Bilgic H, et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum. 2012;64:4078\u201386.","journal-title":"Arthritis Rheum"},{"key":"296_CR31","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/rheumatology\/keu234","volume":"53","author":"M Kondo","year":"2014","unstructured":"Kondo M, Murakawa Y, Matsumura T, et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology (Oxford). 2014;53:1907\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"296_CR32","doi-asserted-by":"publisher","first-page":"e000271","DOI":"10.1136\/rmdopen-2016-000271","volume":"2","author":"N Cabrera","year":"2016","unstructured":"Cabrera N, Duquesne A, Desjonqueres M, et al. Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children. RMD Open. 2016;2:e000271.","journal-title":"RMD Open"},{"key":"296_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1546-0096-12-21","volume":"12","author":"HS Szugye","year":"2014","unstructured":"Szugye HS, Zeft AS, Spalding SJ. Takayasu arteritis in the pediatric population: a contemporary United States-based single center cohort. Pediatr Rheumatol Online J. 2014;12:21.","journal-title":"Pediatr Rheumatol Online J"},{"key":"296_CR34","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.2169\/internalmedicine.51.7954","volume":"51","author":"C Sakai","year":"2012","unstructured":"Sakai C, Kawasaki T, Sakaguchi T, et al. Takayasu arteritis. Intern Med. 2012;51:1937.","journal-title":"Intern Med"},{"key":"296_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1161\/01.CIR.100.1.55","volume":"100","author":"M Noris","year":"1999","unstructured":"Noris M, Daina E, Gamba S, et al. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation. 1999;100:55\u201360.","journal-title":"Circulation"},{"key":"296_CR36","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/art.23373","volume":"58","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Nakahara H, Yoshio-Hoshino N, et al. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008;58:1197\u2013200.","journal-title":"Arthritis Rheum"},{"key":"296_CR37","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3899\/jrheum.130536","volume":"40","author":"E Tombetti","year":"2013","unstructured":"Tombetti E, Franchini S, Papa M, et al. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol. 2013;40:2047\u201351.","journal-title":"J Rheumatol"},{"key":"296_CR38","doi-asserted-by":"publisher","first-page":"e1720","DOI":"10.1542\/peds.2012-1384","volume":"130","author":"B Bravo Mancheno","year":"2012","unstructured":"Bravo Mancheno B, Perin F, Guez Vazquez Del Rey Mdel M, et al. Successful tocilizumab treatment in a child with refractory Takayasu arteritis. Pediatrics. 2012;130:e1720\u20134.","journal-title":"Pediatrics"},{"key":"296_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.semarthrit.2016.07.012","volume":"46","author":"ED Batu","year":"2017","unstructured":"Batu ED, Sonmez HE, Hazirolan T, et al. Tocilizumab treatment in childhood Takayasu arteritis: case series of four patients and systematic review of the literature. Semin Arthritis Rheum. 2017;46:529\u201335.","journal-title":"Semin Arthritis Rheum"},{"key":"296_CR40","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.autrev.2017.11.026","volume":"17","author":"P Decker","year":"2018","unstructured":"Decker P, Olivier P, Risse J, et al. Tocilizumab and refractory Takayasu disease: four case reports and systematic review. Autoimmun Rev. 2018;17:353\u201360.","journal-title":"Autoimmun Rev"},{"key":"296_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/RHU.0000000000000098","volume":"20","author":"CA Canas","year":"2014","unstructured":"Canas CA, Canas F, Izquierdo JH, et al. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol. 2014;20:125\u20139.","journal-title":"J Clin Rheumatol"},{"key":"296_CR42","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/1756-185X.12220","volume":"16","author":"R Goel","year":"2013","unstructured":"Goel R, Danda D, Kumar S, et al. Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis. Int J Rheum Dis. 2013;16:754\u201361.","journal-title":"Int J Rheum Dis"},{"key":"296_CR43","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/BOR.0b013e3283641f61","volume":"25","author":"F Zulian","year":"2013","unstructured":"Zulian F, Cuffaro G, Sperotto F. Scleroderma in children: an update. Curr Opin Rheumatol. 2013;25:643\u201350.","journal-title":"Curr Opin Rheumatol"},{"key":"296_CR44","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/art.40016","volume":"69","author":"N Dumoitier","year":"2017","unstructured":"Dumoitier N, Chaigne B, Regent A, et al. Scleroderma peripheral B lymphocytes secrete Interleukin-6 and transforming growth factor beta and Activate fibroblasts. Arthritis Rheumatol. 2017;69:1078\u201389.","journal-title":"Arthritis Rheumatol"},{"key":"296_CR45","first-page":"321","volume":"33","author":"RA Abdel-Magied","year":"2016","unstructured":"Abdel-Magied RA, Kamel SR, Said AF, et al. Serum interleukin-6 in systemic sclerosis and its correlation with disease parameters and cardiopulmonary involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33:321\u201330.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"296_CR46","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630\u201340.","journal-title":"Lancet"},{"issue":"Suppl 106","key":"296_CR47","first-page":"211","volume":"35","author":"G Martini","year":"2017","unstructured":"Martini G, Campus S, Raffeiner B, et al. Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases? Clin Exp Rheumatol. 2017;35(Suppl 106):211\u20133.","journal-title":"Clin Exp Rheumatol"},{"key":"296_CR48","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/rheumatology\/kex382","volume":"57","author":"H Lythgoe","year":"2018","unstructured":"Lythgoe H, Baildam E, Beresford MW, et al. Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. Rheumatology (Oxford). 2018;57:398\u2013401.","journal-title":"Rheumatology (Oxford)"},{"key":"296_CR49","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/WCO.0000000000000443","volume":"30","author":"RC Dale","year":"2017","unstructured":"Dale RC, Gorman MP, Lim M. Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. Curr Opin Neurol. 2017;30:334\u201344.","journal-title":"Curr Opin Neurol"},{"key":"296_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391\u2013404.","journal-title":"Lancet Neurol"},{"key":"296_CR51","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","volume":"13","author":"WJ Lee","year":"2016","unstructured":"Lee WJ, Lee ST, Moon J, et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics. 2016;13:824\u201332.","journal-title":"Neurotherapeutics"},{"key":"296_CR52","doi-asserted-by":"crossref","unstructured":"Randell RL, Adams AV, Van Mater H. Tocilizumab in refractory autoimmune encephalitis: a series of pediatric cases. Pedatr Neurol. 2018;86:66\u20138.","DOI":"10.1016\/j.pediatrneurol.2018.07.016"},{"key":"296_CR53","doi-asserted-by":"crossref","unstructured":"Migally K, Braunlin EA, Zhang L, et al. Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease. Pediatr Res. 2018;83:1136\u201345.","DOI":"10.1038\/pr.2018.44"},{"key":"296_CR54","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.jacc.2015.12.073","volume":"67","author":"JW Newburger","year":"2016","unstructured":"Newburger JW, Takahashi M, Burns JC. Kawasaki Disease. J Am Coll Cardiol. 2016;67:1738\u201349.","journal-title":"J Am Coll Cardiol"},{"key":"296_CR55","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cyto.2014.07.003","volume":"70","author":"T Fujimaru","year":"2014","unstructured":"Fujimaru T, Ito S, Masuda H, et al. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange. Cytokine. 2014;70:156\u201360.","journal-title":"Cytokine"},{"key":"296_CR56","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMc1709609","volume":"377","author":"T Nozawa","year":"2017","unstructured":"Nozawa T, Imagawa T, Ito S. Coronary-artery aneurysm in tocilizumab-treated children with Kawasaki's disease. N Engl J Med. 2017;377:1894\u20136.","journal-title":"N Engl J Med"},{"key":"296_CR57","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10067-017-3672-z","volume":"36","author":"G Lopalco","year":"2017","unstructured":"Lopalco G, Fabiani C, Sota J, et al. IL-6 blockade in the management of non-infectious uveitis. Clin Rheumatol. 2017;36:1459\u201369.","journal-title":"Clin Rheumatol"},{"key":"296_CR58","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/art.39940","volume":"69","author":"V Calvo-Rio","year":"2017","unstructured":"Calvo-Rio V, Santos-Gomez M, Calvo I, et al. Anti-Interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol. 2017;69:668\u201375.","journal-title":"Arthritis Rheumatol"},{"key":"296_CR59","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3899\/jrheum.160231","volume":"43","author":"C Tappeiner","year":"2016","unstructured":"Tappeiner C, Mesquida M, Adan A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43:2183\u20138.","journal-title":"J Rheumatol"},{"key":"296_CR60","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.survophthal.2015.10.005","volume":"61","author":"MJ Hawkins","year":"2016","unstructured":"Hawkins MJ, Dick AD, Lee RJ, et al. Managing juvenile idiopathic arthritis-associated uveitis. Surv Ophthalmol. 2016;61:197\u2013210.","journal-title":"Surv Ophthalmol"},{"key":"296_CR61","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/09273948.2013.866254","volume":"22","author":"AC Tsang","year":"2014","unstructured":"Tsang AC, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm. 2014;22:155\u20137.","journal-title":"Ocul Immunol Inflamm"},{"key":"296_CR62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00417-013-2466-5","volume":"252","author":"A Adan","year":"2014","unstructured":"Adan A, Mesquida M, Llorenc V, et al. Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. Graefes Arch Clin Exp Ophthalmol. 2014;252:163\u20134.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"296_CR63","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3899\/jrheum.160908","volume":"44","author":"E Quesada-Masachs","year":"2017","unstructured":"Quesada-Masachs E, Caballero CM. Subcutaneous tocilizumab may be less effective than intravenous tocilizumab in the treatment of juvenile idiopathic arthritis-associated uveitis. J Rheumatol. 2017;44:260\u20131.","journal-title":"J Rheumatol"},{"key":"296_CR64","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/BF01546323","volume":"14","author":"MC Kinney","year":"1994","unstructured":"Kinney MC, Hummell DS, Villiger PM, et al. Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease. J Clin Immunol. 1994;14:382\u201390.","journal-title":"J Clin Immunol"},{"key":"296_CR65","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1158\/1535-7163.MCT-11-0972","volume":"11","author":"C Galeotti","year":"2012","unstructured":"Galeotti C, Boucheron A, Guillaume S, et al. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody. Mol Cancer Ther. 2012;11:1623\u20136.","journal-title":"Mol Cancer Ther"},{"key":"296_CR66","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.jpeds.2014.08.042","volume":"165","author":"C Smith","year":"2014","unstructured":"Smith C, Lee-Miller C, Dishop MK, et al. Multicentric Castleman disease presenting with fever. J Pediatr. 2014;165:1261\u20135.","journal-title":"J Pediatr"},{"key":"296_CR67","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/pbc.24761","volume":"61","author":"LM Turcotte","year":"2014","unstructured":"Turcotte LM, Correll CK, Reed RC, et al. Sustained remission of severe multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance. Pediatr Blood Cancer. 2014;61:737\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"296_CR68","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12882-017-0573-y","volume":"18","author":"S Chantarogh","year":"2017","unstructured":"Chantarogh S, Vilaiyuk S, Tim-Aroon T, et al. Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review. BMC Nephrol. 2017;18:159.","journal-title":"BMC Nephrol"},{"key":"296_CR69","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1002\/art.22118","volume":"54","author":"Y Okuda","year":"2006","unstructured":"Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid a amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006;54:2997\u20133000.","journal-title":"Arthritis Rheum"},{"key":"296_CR70","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/annrheumdis-2012-202156","volume":"72","author":"M Hakala","year":"2013","unstructured":"Hakala M, Immonen K, Korpela M, et al. Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-alpha therapy resistant reactive amyloidosis. Ann Rheum Dis. 2013;72:464\u20135.","journal-title":"Ann Rheum Dis"},{"key":"296_CR71","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395.","journal-title":"Blood"},{"key":"296_CR72","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.beha.2017.09.002","volume":"30","author":"N Frey","year":"2017","unstructured":"Frey N. Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol. 2017;30:336\u201340.","journal-title":"Best Pract Res Clin Haematol"},{"key":"296_CR73","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154\u20137.","journal-title":"Blood"},{"key":"296_CR74","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45:e124\u2013e31.","journal-title":"Crit Care Med"},{"key":"296_CR75","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00296-015-3305-2","volume":"35","author":"F Torre La","year":"2015","unstructured":"La Torre F, Muratore M, Vitale A, et al. Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Rheumatol Int. 2015;35:1943\u20137.","journal-title":"Rheumatol Int"},{"key":"296_CR76","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1515\/jpem-2013-0062","volume":"26","author":"S Senniappan","year":"2013","unstructured":"Senniappan S, Hughes M, Shah P, et al. Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome is associated with severe chronic inflammation and cardiomyopathy, and represents a new monogenic autoinflammatory syndrome. J Pediatr Endocrinol Metab. 2013;26:877\u201382.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"296_CR77","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12969-017-0204-y","volume":"15","author":"JL Bloom","year":"2017","unstructured":"Bloom JL, Lin C, Imundo L, et al. H syndrome: 5 new cases from the United States with novel features and responses to therapy. Pediatr Rheumatol Online J. 2017;15:76.","journal-title":"Pediatr Rheumatol Online J"},{"key":"296_CR78","doi-asserted-by":"crossref","unstructured":"Rafiq NK, Hussain K, Brogan PA. Tocilizumab for the treatment of SLC29A3 mutation Positive PHID syndrome. Pediatrics. 2017;140:e20163148.","DOI":"10.1542\/peds.2016-3148"},{"key":"296_CR79","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/rheumatology\/ket211","volume":"53","author":"SM Keidel","year":"2014","unstructured":"Keidel SM, Hoyles RK, Wilkinson NM. Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra. Rheumatology (Oxford). 2014;53:573\u20134.","journal-title":"Rheumatology (Oxford)"},{"key":"296_CR80","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(16)30046-8","volume":"5","author":"WM Wiersinga","year":"2017","unstructured":"Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5:134\u201342.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"296_CR81","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1097\/IOP.0000000000000730","volume":"33","author":"A Sy","year":"2017","unstructured":"Sy A, Eliasieh K, Silkiss RZ. Clinical response to tocilizumab in severe thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2017;33:e55\u20137.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"296_CR82","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.clim.2013.02.017","volume":"147","author":"D Butnaru","year":"2013","unstructured":"Butnaru D, Perez-Moreiras JV, Sanchez-Ramon S. Anti-IL-6R therapy on Graves' ophthalmopathy. Clin Immunol. 2013;147:120\u20131.","journal-title":"Clin Immunol"},{"key":"296_CR83","doi-asserted-by":"crossref","unstructured":"Preez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate to severe corticosteroid resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181\u201390.","DOI":"10.1016\/j.ajo.2018.07.038"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-018-0296-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-018-0296-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-018-0296-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T05:11:48Z","timestamp":1694495508000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-018-0296-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["296"],"URL":"https:\/\/doi.org\/10.1186\/s12969-018-0296-z","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"4 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"79"}}